PCVX FY2025 SEC EDGAR DEF 14A #73 of 168 in industry

Vaxcyte, Inc. CEO pay ratio

The CEO earned $14.6M in FY2025 against median worker pay of $303,873 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#73/168

Data updated August 2026

Subscribe to Vaxcyte, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
48:1
Below Average (Scale: 0–1000:1)
CEO pay
$14.6M
Median worker
$303,873

Answer first

Vaxcyte, Inc.'s FY2025 CEO total of $14.6M ranks #323 of 1,423 complete filings; its 48:1 pay ratio ranks #986. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $303,873. Industry placement uses the FY2025 SIC-28 peer cohort (# 73 of 168, 57th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#323
$14.6M of 1,423 FY2025
Ratio rank
#986
48:1 of 1,423
Industry pct
57th
above the industry median pay ratio

How Vaxcyte, Inc. ranks nationally

Vaxcyte, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$14,585,904 Top 23% higher than 77% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Vaxcyte, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($14.6M) against pay ratio (48:1) for Vaxcyte, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both2820634.87652567.612484500.517316433.422148366.341.6:143.6:145.5:147.4:149.4:1CEO total payPay ratio (CEO : median worker)Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.Alnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Valhi Inc /de/, CEO total pay: 3699168 · Pay ratio (CEO : median worker): 48:1Valhi Inc /de/Madrigal Pharmaceuticals, Inc., CEO total pay: 18959941 · Pay ratio (CEO : median worker): 47:1Madrigal Pharmaceuticals, Inc.Adaptive Biotechnologies Corp, CEO total pay: 9147140 · Pay ratio (CEO : median worker): 47:1Adaptive Biotechnologies CorpViking Therapeutics, Inc., CEO total pay: 21269833 · Pay ratio (CEO : median worker): 49:1Viking Therapeutics, Inc.
Vaxcyte, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Vaxcyte, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Vaxcyte, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
48:1
FY2025
vs prior FY
-75:1
from FY2024 123:1
CEO $ YoY
-63%
$14.6M latest
Filings shown
4
FY2022–2025
Vaxcyte, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $13.7M - $274,403 50:1 -
2023 $12.2M -11% $276,484 44:1 -6:1
2024 $39.8M +227% $323,387 123:1 +79:1
2025 $14.6M -63% $303,873 48:1 -75:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1649094, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
48:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$14.6M
Companies in Industry
168
vs. Industry Median
Above
#73 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Vaxcyte, Inc.: MODEST · HEAVY pay ratio

Vaxcyte, Inc.'s FY2025 CEO total $14.6M ranks #323 of 1,423 complete filings (higher third by dollars). the CEO earned 48× the median employee ($303,873) in FY2025.

Median employee $303,873 (ELITE-MED); MODEST · HEAVY stamps put about 48 median-wage years per CEO year.

CEO Total Pay

$14.6M

FY2025 Summary Compensation, above median

Pay Ratio

48:1

Below typical

Vaxcyte, Inc. in the higher-dollar third

Vaxcyte, Inc.'s FY2025 CEO total $14.6M ranks #323 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Vaxcyte, Inc.'s $14.6M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #323 and ratio rank #986 split - treat 48:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$14.6M
Median Employee Pay
$303,873
Pay Ratio
48:1
Filing Date
2026-04-23

Company Info

Ticker
PCVX
CIK
1649094
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1649094, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Vaxcyte, Inc.'s FY2025 CEO total $14.6M ranks #323 of 1,423 complete filings (higher third by dollars).

Read with Vaxcyte, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Porch Group, Inc. · HEAVY

ABS(ceo_total_comp) peer at $14.6M (Δ $6K lighter vs Vaxcyte, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
LPL Financial Holdings Inc. · HEAVY

ABS(ceo_total_comp) peer at $14.6M (Δ $11K lighter vs Vaxcyte, Inc.); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Huntsman CORP · HEAVY

ABS(ceo_total_comp) peer at $14.6M (Δ $64K heavier vs Vaxcyte, Inc.); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Kb Home · HEAVY

ABS(ceo_total_comp) peer at $14.7M (Δ $124K heavier vs Vaxcyte, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Alnylam Pharmaceuticals, Inc. (SIC 28 pole)

Alnylam Pharmaceuticals, Inc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Vaxcyte, Inc.'s MODEST filing.
National dual ranks · #323/#986

Vaxcyte, Inc.'s FY2025 package sits #323 by CEO dollars and #986 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Vaxcyte, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Vaxcyte, Inc. (CIK 1649094), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.